In this regard, the outside world can not help speculating, this round of inspection, will dig out more than the previous period of continuous fermentation of Kangmei Pharmaceutical financial fraud incident thunderbolt? After all, a year ago, Kangmei Pharmaceutical Co. was one of the big white horses in A-share market, a few hundred billion pharmaceutical companies with market value, and Yunnan Baiyao Co. (75.230, -0.83, -1.09%) and Fuxing Pharmaceutical Co. (Fosun Pharmaceutical Co.) were called "Baifumei" in A-share market, which was the long-term target favored by value investors. A year later, Kangmei Pharmaceutical was put on the ST hat because of the 30 billion yuan cash fake account problem, and faced the risk of delisting. Another A-share listed company, Changsheng Biology, has become * ST Changsheng (1.510, 0.00, 0.00%) because of vaccine fraud (rights protection).
In addition, the industry believes that the high cost of sales is the characteristics of the pharmaceutical industry, the market may look at this action of the Ministry of Finance in a negative light. Today's stock prices on the list did not perform well. Tongrentang fell 4.12%, Fuxing Pharmaceutical fell 3.04%, and Shanghai Pharmaceutical fell 1.04%.
Hot Model No.: